Corporate Update: Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Co. Ltd. (Takeda) submitted a Form 4 to the U.S. Securities and Exchange Commission on 15 September 2026, reporting a change in the ownership of its American Depositary Shares (ADS) by an individual who holds an officer position within the company. The filing details the acquisition of additional shares by this officer, increasing their overall stake to roughly 191,000 shares. The transaction was completed at a price in the mid‑tens of dollars per share, reflecting a typical market level for the company’s securities.
No other material events or corporate actions were disclosed in the filing. The update confirms the continued participation of a senior executive in the company’s equity base and provides a snapshot of Takeda’s share ownership structure at the close of the reporting period.
